(69) Evaluating Crisaborole 2% Ointment's Role in Improving Quality of Life in Patients Three Months and Older with Mild to Moderate Atopic Dermatitis: A Systematic Review
Background: Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory skin disease that occurs in 11 to 15% of children in the United States and 7.3% in adults. The impact of AD is comparable to diabetes and places a substantial social and financial burden on families and society, especially because current treatment options do not provide sustained remission or cure.
Objectives: The primary objective of this systematic review is to evaluate the impact of crisaborole treatment on the quality of life in patients three months and older with mild-to-moderate AD. This systematic review emphasizes the relationship between changes in signs and symptoms of AD due to crisaborole-treatment and patient’s quality of life.
Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The databases searched included PubMed and ClinicalTrials.Gov. The search terms “(Crisaborole OR Eucrisa) AND (Atopic dermatitis OR Eczema)” were searched from inception to February 10, 2022. Results were narrowed using the “English” and “human” filters. Only studies that had published results were included in our search from ClinicalTrials.gov. High quality studies such as randomized controlled trials and meta-analyses that were relevant to our objective were carefully selected and analyzed for this systematic review.
Results: A total of 13 PubMed articles and 1 trial (NCT03539601) from ClinicalTrials.Gov were included in this systematic review. These studies include two meta-analyses, three open label studies, three randomized controlled trials, four post hoc analyses, one claims analysis, and one mediation analysis. The total number of patients ranged from 34 patients to 4386 in each of these studies. Crisaborole’s effect on the quality of life was found to be about half (51.4%) the total effect of treatment on Dermatology Life Quality Index [DLQI] (p = 0.0272), and about three-fourths (72.4%) the total effect of treatment on Children’s Dermatology Life Quality Index [CDLQI] (p < 0.0001). Furthermore, crisaborole is safe with treatment emergent adverse events (TEAEs) reported to be mild to moderate with spontaneous remission.
Conclusions: This systematic review shows that crisaborole improves the quality of life of patients by improving reducing pruritis severity from baseline. Long-term studies directly comparing the cost of benefit and effectiveness of crisaborole to current recommended treatment are stilled needed to evaluate crisaborole’s role in management of mild to moderate AD.
